Aarey Drugs

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: INE198H01019
  • NSEID: AAREYDRUGS
  • BSEID: 524412
INR
83.48
3.19 (3.97%)
BSENSE

Jun 18

BSE+NSE Vol: 51.57 k

  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy
Comparison
Company
Score
Quality
Valuation
Financial
Technical
Ambalal Sarabhai
Quest Laborato.
Syschem (India)
Aarey Drugs
Gennex Lab.
Brooks Lab.
Nectar Lifesci.
Kerala Ayurveda
Accretion Nutrav
Speciality Medi.
Sat Kartar Life
Why is Aarey Drugs & Pharmaceuticals Ltd ?
1
Weak Long Term Fundamental Strength with a -159.74% CAGR growth in Operating Profits over the last 5 years
  • Company's ability to service its debt is weak with a poor EBIT to Interest (avg) ratio of 1.87
  • The company has been able to generate a Return on Equity (avg) of 4.20% signifying low profitability per unit of shareholders funds
2
The company has declared Negative results for the last 3 consecutive quarters
  • PAT(9M) At Rs 2.86 cr has Grown at -42.69%
  • PBT LESS OI(Q) At Rs 0.69 cr has Fallen at -60.12%
  • NET SALES(Q) At Rs 84.16 cr has Fallen at -19.95%
3
Risky - Negative Operating Profits
  • The stock is trading risky as compared to its average historical valuations
  • Over the past year, while the stock has generated a return of 19.96%, its profits have fallen by -40.4%
4
Falling Participation by Institutional Investors
  • Institutional investors have decreased their stake by -0.84% over the previous quarter and collectively hold 1.13% of the company
  • These investors have better capability and resources to analyse fundamentals of companies than most retail investors
stock-recommendationReal-Time Research Report
Verdict Report
How much should you hold?
  1. Overall Portfolio exposure to Aarey Drugs should be less than 10%
  2. Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock

Is Aarey Drugs for you?

High Risk, High Return

Absolute
Risk Adjusted
Volatility
Aarey Drugs
48.44%
0.44
44.97%
Sensex
-4.95%
0.43
11.83%
stock-recommendationQuality
stock-summaryManagement Risk
stock-summaryGrowth
stock-summaryCapital Structure
stock-recommendation
Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors
Factor
Value
Sales Growth (5y)
7.24%
EBIT Growth (5y)
3.09%
EBIT to Interest (avg)
1.55
Debt to EBITDA (avg)
7.16
Net Debt to Equity (avg)
0.32
Sales to Capital Employed (avg)
2.81
Tax Ratio
16.45%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
5.80%
ROCE (avg)
2.55%
ROE (avg)
3.75%
stock-recommendationValuation
Valuation Scorecard stock-summary
stock-recommendation
Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors stock-summary
Factor
Value
P/E Ratio
52
Industry P/E
23
Price to Book Value
1.57
EV to EBIT
66.03
EV to EBITDA
39.73
EV to Capital Employed
1.43
EV to Sales
0.60
PEG Ratio
4.31
Dividend Yield
NA
ROCE (Latest)
2.17%
ROE (Latest)
3.00%
Loading Valuation Snapshot...
stock-recommendationTechnicals
Technical key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Mildly Bearish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Bullish
Bullish
Dow Theory
Mildly Bullish
Mildly Bullish
OBV
No Trend
Bullish
stock-recommendation Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
Technical Movement
stock-recommendationFinancial Trend
Financial Trend Scorecard stock-summary
stock-recommendation
Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

13What is working for the Company
NET SALES(Q)

Highest at Rs 189.47 cr

PBDIT(Q)

Highest at Rs 4.34 cr.

PBT LESS OI(Q)

Highest at Rs 1.71 cr.

PAT(Q)

Highest at Rs 1.56 cr.

EPS(Q)

Highest at Rs 0.55

0What is not working for the Company
Icon
NO KEY NEGATIVE TRIGGERS
Loading Valuation Snapshot...
Here's what is working for Aarey Drugs
Profit Before Tax less Other Income (PBT) - Quarterly
At Rs 1.71 cr has Grown at 128.93%
Year on Year (YoY)
MOJO Watch
Near term PBT trend is very positive

PBT less Other Income (Rs Cr)

Profit After Tax (PAT) - Quarterly
At Rs 1.56 cr has Grown at 231.9%
Year on Year (YoY)
MOJO Watch
Near term PAT trend is very positive

PAT (Rs Cr)

Net Sales - Quarterly
At Rs 189.47 cr has Grown at 75.27%
Year on Year (YoY)
MOJO Watch
Near term sales trend is very positive

Net Sales (Rs Cr)

Net Sales - Quarterly
Highest at Rs 189.47 cr
in the last five quarters
MOJO Watch
Near term sales trend is positive

Net Sales (Rs Cr)

Operating Profit (PBDIT) - Quarterly
Highest at Rs 4.34 cr.
in the last five quarters
MOJO Watch
Near term Operating Profit trend is positive

Operating Profit (Rs Cr)

Profit Before Tax less Other Income (PBT) - Quarterly
Highest at Rs 1.71 cr.
in the last five quarters
MOJO Watch
Near term PBT trend is positive

PBT less Other Income (Rs Cr)

Profit After Tax (PAT) - Quarterly
Highest at Rs 1.56 cr.
in the last five quarters
MOJO Watch
Near term PAT trend is positive

PAT (Rs Cr)

Earnings per Share (EPS) - Quarterly
Highest at Rs 0.55
in the last five quarters
MOJO Watch
Increasing profitability; company has created higher earnings for shareholders

EPS (Rs)